Research progress of hypoxia-inducible factor-prolyl hydroxylase inhibitor in vascular calcification in chronic kidney disease
LI Lin
YOU Yanwu
Abstract：Hypoxia-inducible factor-prolyl hydroxylase inhibitor(HIF-PHI)is a novel drug for treating renal anemia in chronic kidney disease(CKD).As a stabilizer of hypoxia-inducible factor(HIF),HIF-PHI can increase the expression level of HIF,and the continuous increase of HIF can promote the osteogenic transdifferentiation and calci-fication of vascular smooth muscle cells,which has the risk of increasing vascular calcification.Long-term use of HIF-PHI may have the potential risk of vascular calcification.Vascular calcification is a major risk factor for the increase of inci-dence rate and mortality rate of cardiovascular events in CKD patients.Therefore,the potential hazards of HIF-PHI should be fully understood and taken seriously.This paper reviews the research progress of HIF-PHI in vascular calcification in CKD.
Keywords：Hypoxia-inducible factor-prolyl hydroxylase inhibitor(HIF-PHI)Hypoxia-inducible factor(HIF)Vascular calcificationChronic kidney disease(CKD)
Publication Date：2024-08-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 866-870 )